| Ranbaxy finding ways to make two of four acquisitions work | 16-NOV-09 |
|
| The key strategic investments made by the erstwhile promoters of Ranbaxy Laboratories may seem to be floundering on the surface, but the Daiichi-owned company is looking at bigger engagements with at least two of these companies. |
|
|
|
|
|
|
| Ranbaxy Labs reports net profit of Rs 116 cr | 27-OCT-09 |
|
| India’s biggest drug maker, Ranbaxy Laboratories, has posted a net profit of Rs 116.6 crore for its third quarter ended September, against a net loss of Rs 394.5 crore in the same period last year, which had been largely attributed to mark-to-market exchange losses. |
|
|
|
| Ranbaxy wins US court ruling on Roche patent | 17-OCT-09 |
|
| Daiichi Sankyo-owned Ranbaxy Laboratories has won a decisive ruling from the District Court of New Jersey that its generic version of valganciclovir, prescribed for HIV/Aids patients and for organ transplantation-related infections, does not infringe the patent rights of Swiss drug maker Roche's anti-infection drug, Valcyte. |
|
|
|
|
|
|
| Ranbaxy to market S Korean product | 18-SEP-09 |
|
| Ranbaxy Laboratories Ltd has entered into an in-licencing agreement with South Korean biotech firm Medy-Tox Inc for supply of its dermatology product Neuronox in the Indian market. |
|
|
|
| SC pulls up Ranbaxy for delayed raising of refund issue | 24-AUG-09 |
|
| The Supreme Court has admonished drug major Ranbaxy Laboratories Ltd for not raising on the relevant occasion the issue of refunding Rs 1 crore penalty the government had imposed on it for allegedly overcharging drug prices. |
|
|
|
| Ranbaxy up 4.5% on launch | 13-AUG-09 |
|
| The Ranbaxy Laboratories scrip rose 4.5 per cent to Rs 289.55 on protein supplement launch. The company entered the protein foods market with the launch of the ‘Revitalite’ brand. The company is present in the nutritional supplement market through its brand “Revital”; the launch of “Revitalite” further strengthens the company's position in this space. |
|
|
|
|
|
|
|
|
|
| Ranbaxy recalls drug from US mkt | 10-JUL-09 |
|
| Pharma major Ranbaxy Laboratories today said its US-based subsidiary, Ranbaxy Laboratories Inc Priceton NJ, was recalling capsules used in the treatment of acne (a type of skin disease) from the US market. |
|
|
|
| Wal-Mart faces ire over drugs from Ranbaxy | 26-JUN-09 |
|
| More trouble is brewing for the Daiichi Sankyo-owned Ranbaxy Laboratories in the US, as a campaign has been unleashed against the world’s largest retailer, Wal-Mart, for selling drugs manufactured by Ranbaxy. |
|
|
|
| Daiichi Sankyo to raise $1 bn through bonds issue | 17-JUN-09 |
|
| Japanese drug maker Daiichi Sankyo, the majority shareholder in Indian pharma major Ranbaxy Laboratories, plans to raise 100 billion yen (about $1.04 billion) through public issue of bonds. |
|
|
|
| Making Ranbaxy 'Singh' again | 01-JUN-09 |
|
| The board meeting of Ranbaxy Laboratories, India’s largest pharmaceutical company in terms of sales, lasted all of two hours at The Oberoi in New Delhi. At the end of it, Malvinder Mohan Singh stepped down as the chief executive of the company. In his place, Atul Sobti was appointed managing director and CEO for a three-year term. |
|
|
|
| Daiichi full-year losses narrow down to $2.2 bn | 29-MAY-09 |
|
| Japanese drug maker Daiichi Sankyo, which has a controlling stake in Indian pharma major Ranbaxy Laboratories, has narrowed its full-year losses at 215.59 billion yen (about $2.2 billion) on account of changes related to accounting guidelines in Japan. |
|
|
|
Content Guide
